As part of the $100 million deal, the companies will collaborate to develop more than 10 experimental drugs to treat conditions such as cardio-metabolic disorders and pain.
To expand its gene-silencing portfolio, Eli Lilly will pay $100 million upfront and buy a $100 million equity stake. Under the deal, Dicerna is eligible to receive up to $350 million and some royalties for each developed drug.
Gene-silencing technology works by targeting and turning off certain genetic material in an effort to prevent some disease-causing proteins from forming.
Johnson and Johnson has also recently invested in gene silencing firms.
More articles on pharmacy:
Drug take back day is Oct. 27: 5 things to know
Amgen cuts list price of $14K-a-year cholesterol drug nearly 60%
Trump’s plan to lower prescription drug prices: 7 takeaways
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.